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 FIGURE S1: EFFECT OF CHLOROQUINE ON MELANOMA CELL PROLIFERATION AND SURVIVAL 
(RELATED TO FIGURE 1) 
(A, B) Immunoblot with densitometric quantification of LC3II and p62 protein levels, relative to 
actin, in A375m (A) or B16-F10 (B) cells treated with different doses of CQ (n = 3). (C) 
Immunostaining for LC3 in A375m cells after CQ (25 µM) treatment versus control. 
Quantification of autophagosomes/cell is indicated (n = 3). (D) Clonogenic growth of A375m 
cells in the absence or presence of CQ (10 µM). (E, F) Proliferation (E) and cell death 
(propidium iodide (PI) exclusion assay) (F) of A375m cancer cells in the presence of 
increasing concentrations of CQ in control (nutrient-rich + normoxia) and ischemic (starvation 
+ 0.5% O2) conditions (n = 3). (G) Clonogenic growth of B16-F10 cells in the absence or 
presence of CQ (10 µM). (H, I) Proliferation (H) and cell death (I) of B16-F10 cancer cells in 
the presence of increasing concentrations of CQ in control (nutrient-rich + normoxia) and 
ischemic (starvation + 0.5% O2) conditions (n = 3). (J) Representative micrographs of 
immunostaining for CQ of B16-F10 tumor sections. Quantification of CQ+ area (% of total 
area) is indicated (n = 3). (K) GC-MS measurement of CQ levels in B16-F10 tumors in control 
and CQ-treated (50 or 100 mg/kg/day) mice in vivo assessed at one hr after CQ injection (n = 
3), and of CQ levels in cultured B16-F10 cancer cells exposed to CQ (5 or 10 µM) or vehicle in 
vitro (n = 3). CQ levels in cancer cells treated with 25 µM CQ could not be determined 
because these cancer cells died. ND, not detectable. (L, M) Immunoblot with densitometric 
quantification of LC3II protein levels relative to actin from B16-F10 (L) or A375m (M) tumors 
treated with CQ (50 or 100 mg/kg/day) or vehicle (n = 3). (N, O) Quantification of cancer cells 
with PHH3+ positive nuclei displaying identifiable mitotic spindles in A375m (n = 6) (N) or B16-
F10 tumors (n = 4-6) (O). (P) Analysis of necrotic area in size-matched A375m tumors after 
CQ treatment (50 mg/kg/day) as compared to control treated tumors (n = 11-12). (Q, R) 
Analysis of TUNEL staining in size-matched A375m (n = 4-7) (Q) or B16-F10 (n = 7-11) (R) 
tumors after CQ treatment (50 or 100 mg/kg/day) as compared to control treated tumors. (S, 
T) Quantification of PI+ dead B16-F10 (n = 6-9) (S) or A375m (n = 9) (T) cancer cells, isolated 
from tumors of mice treated with PBS or CQ (50 or 100 mg/kg/day), and cultured in control 
conditions (nutrient rich + normoxia) or ischemia (starvation + 0.5% O2) in the presence of 
increasing concentrations of CQ. (U) qRT-PCR analysis of the expression level of pro-survival 
genes in B16-F10 tumors treated with PBS or CQ (50 or 100 mg/kg/day) (n = 4-5). (V) 
 Quantification of metastatic nodule area (% of total lung area) from control and CQ treated 
mice (n = 5-7). (W) Quantification of B16-F10 cancer cell invasion into Matrigel upon CQ 
treatment (n = 3). (X) Immunostaining for CD45+ of B16-F10 tumors treated with PBS or CQ 
(50 or 100 mg/kg/day). Quantification (CD45+ area, % of total area) is indicated (n = 4-6). Bar: 
10 µm (C), 100 µm (J), 50 µm (X). All quantitative data are mean ± SEM. 
 
 
 
  
   
 FIGURE S2: EFFECT OF CHLOROQUINE ON VESSEL STRUCTURE AND MATURATION IN VIVO (RELATED 
TO FIGURE 2)   
(A) Immunostaining for the EC marker CD31 and the vessel maturation marker αSMA in 
healthy skin and in human melanoma. Nuclei are visualized by DAPI staining. Arrows denote 
pericyte coverage. (B) Confocal micrographs of immunostaining for CD31 of thick sections of 
control and CQ-treated tumors (50 or 100 mg/kg/day). (C-E) immunostaining for CD31 of 
A375m tumors in control and CQ-treated (50 mg/kg/day) mice (C) and quantification of vessel 
density (D), and tortuosity (E) (n = 10). (F, G) Double immunostaining for CD31 and αSMA in 
control and CQ–treated (50 mg/kg/day) A375m xenografts (F) and quantification of % of 
pericyte covered vessels (G) (n = 11). (H) Scanning electron microscopy of A375m tumor 
vessels in control and CQ–treated (50 mg/kg/day) tumors. Bar: 100 µm (C), 50 µm (A, B, F), 5 
µm (H). All graphs show mean ± SEM. 
  
  
 
 
 
 
  
 FIGURE S3: EFFECT OF CQ ON VESSEL FUNCTION AND TUMOR CHEMOSENSITIVITY (RELATED TO 
FIGURE 3) 
(A, B) Representative micrographs of lectin-FITC perfused and CD31-immunostained vessels 
in CQ-treated (50 kg/mg/day) and control size-matched A375m tumors (A) and quantification 
of CD31+lectin+ area, % of total CD31+ area (B) (n = 5-7). (C, D) Representative micrographs 
of pimonidazole (PIMO) staining (C) and quantification (D) of hypoxic zones in A375m tumors 
from control and CQ-treated (50 kg/mg/day) mice (n = 8-10). (E) Representative images (H&E 
staining) of necrotic area (asterisks within dashed lines) in B16-F10 tumors after single or 
combined treatment with a suboptimal dose of cisplatin (CPt; 2.5 mg/kg every other day) and 
CQ (50 mg/kg/day). (F, G) Primary tumor growth (end-stage tumor volume relative to tumor 
volume at the start of DITC treatment) (F) and pulmonary metastasis (G) of B16-F10 tumors 
upon single or combined treatment with CQ (50 mg/kg/day) and dacarbazine (DTIC) (n = 14-
17). Bar: 100 μm (A, E), 50 μm (C). All graphs show mean ± SEM; * p < 0.05 and ** p < 0.01 
versus the corresponding control (no CQ), # p = 0.07 versus CQ only. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 FIGURE S4: EFFECT OF ATG5 SILENCING ON CANCER CELL GROWTH AND SURVIVAL IN VITRO AND 
ON METASTASIS, VESSEL MORPHOLOGY AND FUNCTION IN VIVO (RELATED TO FIGURE 4) 
(A) Immunoblot with densitometric quantification of LC3II and ATG5 protein levels relative to 
actin in cells transduced with a shRNA-ATG5 (shATG5) lentivirus as compared to control (ctrl) 
(n = 4). Actin was used as a loading control (bottom row). (B) Analysis of proliferation (3H-
thymidine incorporation) in ctrl and shATG5 B16-F10 cancer cells (n = 4-6). (C) Clonogenic 
growth of B16-F10 cancer cells upon ATG5 silencing as compared to control. (D) Cell death 
(propidium iodide exclusion) in ctrl and shATG5 B16-F10 cells in control (nutrient rich + 
normoxia) and ischemic (starvation + 0.5% O2) conditions (n = 3). (E) Quantification of 
metastatic index of control and shATG5 B16-F10 cancer cells (n = 13-18). (F) Representative 
micrographs of pimonidazole (PIMO) staining of hypoxic zones in size-matched B16-F10 
tumors generated with control as compared to shATG5 cancer cells. Quantification is 
indicated (n = 7-12). (G) Quantification of vessel tortuosity in control and shATG5 B16-F10 
tumors (n = 4). Bar: 200 μm (F). All quantitative data are mean ± SEM.  
   
  
 
 
 
 
 
 
 
 FIGURE S5: EFFECT OF CHLOROQUINE AND ATG5 SILENCING ON ENDOTHELIAL CELL RESPONSES IN 
VITRO (RELATED TO FIGURE 5) 
(A) qRT-PCR analysis of pro-angiogenic genes in B16-F10 tumors from mice treated with CQ 
(50 or 100 mg/kg/day) or PBS (n = 6-10). (B) Immunoblot with densitometric quantification of 
LC3II and p62 protein levels relative to actin in ECs treated with CQ (5-25 µM) as compared to 
control (ctrl) (n = 3). (C-H) Analysis of EC spheroid sprouting upon control or CQ treatment 
under starvation (C-E) or hypoxia (F-H). Representative micrographs in E (starvation) and H 
(hypoxia); morphometric quantification of sprout number and total sprout length in C, D 
(starvation) and F, G (hypoxia) (n = 19-21). (I, J) Analysis of EC migration (scratch wound 
assay) (I) or proliferation (3H-thymidine incorporation) (J) upon CQ treatment as compared to 
ctrl (n = 3). (K) Propidium iodide (PI) exclusion analysis of ECs in control (nutrient-rich + 
normoxia) and ischemic (starvation + 0.5% O2) conditions and treated with increasing 
concentrations of CQ (n = 3). (L) Immunoblot with densitometric quantification of LC3II and 
ATG5 protein levels relative to actin in ECs transduced with a shATG5 lentivirus as compared 
to control (ctrl) (n = 6-9). (M-O) Representative micrographs (M) of EC spheroids of ATG5-
silenced ECs (shATG5) as compared to control ECs and quantification of sprout number (N) 
and total sprout length (O) (n = 30). (P, Q) Analysis of migration (scratch wound) (P) or 
proliferation (3H-thymidine incorporation) (Q) of ctrl and shATG5 HUVECs (n = 3). (R) 
Propidium iodide (PI) exclusion analysis of ctrl and shATG5 HUVECs in control and ischemic 
conditions (n = 3). (S) Scanning electron microscopy of B16-F10 tumor vessels from ctrl and 
Atg5EC-KO mice. Bar: 100 μm (E, H, M), 5 μm (S). All quantitative data are mean ± SEM. 
  
   
 FIGURE S6: EFFECT OF CQ ON NOTCH1 LOCALIZATION AND SIGNALING IN THE LATE ENDOSOMES 
(RELATED TO FIGURE 6)     
(A, B) Immunostaining for LAMP1 of ECs treated with CQ (25 μM) as compared to control (A) 
and quantification (B) (n = 10). (C, D) Double immunostaining for the LE marker CD63 and 
VE-cadherin of ctrl and CQ treated ECs (C) and quantification (D) of VE-cadherin+ area per 
cell (n = 10). (E-H) Double immunostaining (E, G) for Notch1 and EEA1 (E), or Notch1 and 
LAMP1 (G) of ECs treated with CQ as compared to ctrl and quantification of colocalization of 
Notch1 with EEA or LAMP1: Pearson coefficient (PC) (F, H, respectively) (n = 10). (I) qRT-
PCR analysis of NOTCH1 expression in CQ-treated (5-25 μM) ECs as compared to control 
ECs (n = 3). Insets in A, E, G show magnifications of the boxed areas. Bar: 10 µm in all 
micrographs. All quantitative data are mean ± SEM. 
 
  
   
  
 
  
 FIGURE S7: EFFECT OF CQ ON NOTCH1 SIGNALING IN ECS (RELATED TO FIGURE 7)    
(A, B) Densitometric quantification of Notch1 NICD (A), p120 (B) of immunoblots shown in Fig. 
7A (n = 9-11). (C) Immunoblotting with an antibody detecting C-terminal Notch1 of ECs treated 
with CQ and/or the γ-secretase inhibitor DAPT. Densitometric quantification of the different 
Notch1 cleavage products is shown below the respective lanes (n = 3). (D) Densitometric 
quantification of Notch1 NEXT of immunoblots shown in Fig. 7A (n = 9-11). (E) Analysis of γ-
secretase activity in ECs treated with CQ or DAPT. Densitometric quantification is shown 
below the lanes (n = 3). (F-J) Immunoblotting (F-H) and densitometric quantification of Notch1 
fragments (I, J) of EC lysates with an antibody detecting C-terminal Notch1 at different time 
points during treatment with control (F, I, J), CQ (25 µM) (G, I, J) or DLL4 (H-J), in the 
presence or absence of the γ-secretase inhibitor DAPT. All cells were treated with the protein 
synthesis inhibitor cycloheximide during the time course of the experiment (n = 6). (K) 
Immunoblotting for Notch1 NICD of ECs treated with CQ, DLL4 (2 μg/mL) or vehicle, and with 
or without the proteasome inhibitor lactacystin (LAC; 10 μM). Densitometric quantification is 
shown below each lane (n = 3). (L) HES1 luciferase reporter assay in ECs treated with CQ for 
the indicated time periods (n = 6). (M) Immunoblotting for NICD in nuclear and cytoplasmic 
extracts of ECs treated with bafilomycin A1 (Baf) (5 nM) or vehicle for 24 hr. Loading control of 
the nuclear (lamin) and cytoplasmic (GAPDH) fractions is shown. Densitometric quantification 
is shown below the lanes (n = 3). (N) Immunoblotting for DLL4 or Jagged-1 of ECs treated 
with CQ (5-25 μM) or vehicle. Actin is used as a loading control. Densitometric quantification is 
shown below each lane (n = 3). (O) Immunoblotting of EC lysates for different Notch1 
cleavage products in ctrl and Notch1-silenced (Notch1KD) ECs treated with CQ or vehicle. 
Densitometric quantification is shown below each lane (n = 3). All quantitative data are mean ± 
SEM. 
  
  
                                                                                                                                                        
 FIGURE S8: EFFECT OF GENETIC DEFICIENCY OF NOTCH2, NOTCH3, OR NOTCH4 SIGNALING IN ECS 
ON CQ PHENOTYPES (RELATED TO FIGURE 8)    
(A, B) Representative micrographs (A) and quantification of sprout length (B) of EC spheroids 
treated with CQ and/or DAPT. Note that inhibition of Notch1 signaling by DAPT induces 
hyperbranching of the spheroids (n = 30). (C-F) Representative micrographs (C) and 
quantification of sprout number (D) and sprout length (E) of spheroids of Notch2-, Notch3- or 
Notch4-silenced ECs as compared to control scrambled shRNA-treated ECs (ctrl) in the 
presence or absence of CQ (n = 30). (F) qRT-PCR verification of silencing of indicated Notch 
receptor (n = 4-6). Bars: 100 μm (A, C). All quantitative data are mean ± SEM. 
  
 SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
ANIMALS: C57BL/6 mice were from the KU Leuven mouse facility or were purchased from 
Janvier (France). Nu/nu mice were purchased from Janvier (France).  
CHEMICALS AND REAGENTS: Collagen type 1 (rat tail) was from Millipore or Novagen (Merck, 
Germany). N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), 
dynamin inhibitor I (Dynasore) and lactacystin were from Merck Millipore (Overijse, Belgium). 
Endothelial Cell Growth Supplements (ECGS), bovine serum albumin (BSA), methylcellulose, 
heparin, chloroquine diphosphate (CQ), bafilomycin A1, dacarbazine (5-(3,3-Dimethyl-1-
triazenyl) imidazole-4-carboxamide; DTIC), propidium iodide (PI), methylene blue and 
polybrene, cisplatin and cycloheximide were from Sigma-Aldrich (Bornem, Belgium). 
Endothelial growth medium (EGM2) was from Clonetics (Lonza, Braine-l’Alleud, Belgium). L-
glutamine, sodium pyruvate, penicillin/streptomycin, and puromycin were from Gibco® 
(Invitrogen, Life Technologies, Ghent, Belgium). Recombinant human (rh) DLL4 extracellular 
domain protein was from R&D Systems, USA. Specifics on other chemicals used in specific 
assays or procedures are mentioned in the respective methodology sections. 
CELL CULTURE: PRIMARY CELLS: Human umbilical vein ECs (HUVECs) were freshly isolated 
from different donors as previously described (Jaffe et al., 1973) and used between passage 1 
and 5. HUVECs were cultured on 0.1% gelatin coated dishes in endothelial basal medium 
(EBM-2) supplemented with endothelial growth medium SingleQuots (Clonetics, Lonza, 
Braine-l’Alleud, Belgium). For starvation conditions, HUVECs were cultured in EBM-2 medium, 
0,5% fetal bovine serum (FBS) without SingleQuots. CANCER CELL LINES: A375m cells were 
maintained in DMEM containing 10% FBS (HyClone, ThermoFisher scientific, USA) and 4 mM 
L-Glutamine and Penicillin / Streptomycin. B16-F10 cells were cultured in RPMI containing 
10% FBS and 2 mM glutamine (cell culture reagents were from Sigma-Aldrich, Bornem, 
Belgium, unless mentioned otherwise). For starvation conditions, the cancer cells were 
cultured in medium without FBS.  All cells were routinely maintained in 5% CO2 and 95% air 
at 37 °C. For hypoxic conditions cells were maintained in an Invivo2 400 hypoxia workstation 
(Ruskinn, LED techno, Heusden-Zolder, Belgium) at 5% CO2, 94.5% N2 and 0.5% O2 at 37 °C 
for the indicated time periods. For ischemia conditions, starvation conditions were combined 
with hypoxic conditions. To assess whether cancer cells upon CQ treatment in vivo acquire 
 resistance to CQ treatment, we isolated B16-F10 and A375m tumor at the end stage of 
experiment (2,000 mm3 and 1,000 mm3 for B16-F10 m and A375tumors, respectively) and 
analyzed the effect of CQ on cell death in vitro. Cancer cells were isolated after collagenase 
digestion (collagenase type L; Sigma Aldrich, Bornem, Belgium) and were depleted from 
contaminating stromal cells, which display higher adherence than cancer cells, by differential 
plating. Thirty min after plating, non-adherent cancer cells were plated into a new tissue 
culture flask and washed 24 hr later to remove cell debris. Cells were then used for 
experimentation within 72 hr.  
COMPOUND TREATMENTS: AUTOPHAGY INHIBITION: Subconfluent cells were cultured in the 
presence of chloroquine diphosphate (CQ) for the indicated time periods and at the indicated 
concentrations. NOTCH PATHWAY MODULATION: To activate the Notch pathway, cells were grown 
for the indicated time periods on plates coated with recombinant human (rh) DLL4 
extracellular domain at a final concentration of 0, 0.5 or 2 μg/mL as previously described, 
using bovine serum albumin (BSA) coated plates as control. Pharmacological inhibition of 
Notch activation was achieved by culturing the cells in the presence of 10 µM of the γ-
secretase inhibitor N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester 
(DAPT) for the indicated time periods. INTERFERENCE WITH CELLULAR DEGRADATION: To block 
lysosomal degradation, cells were treated for 24 hr either with chloroquine (0, 5, 10 or 25 µM) 
or the inhibitor of the vacuolar H+ ATPase bafilomycin A1 (5 nM). To block proteasomal 
degradation, cell were treated for 3 hr with lactacystin (10 μM). INTERFERENCE WITH 
ENDOCYTOSIS: Pharmacological inhibition of endocytosis by blocking dynamin, which is 
necessary for clathrin-dependent coated vesicle formation, was achieved by use of 40 µM of 
Dynasore.   
RNA INTERFERENCE: SIRNA TRANSFECTIONS: To lower the protein levels of Notch1, Notch2, 
Notch3 or Notch4, HUVECs were transfected with siRNA targeting the respective Notch 
receptor RNA (Trifekta Kit, IDT). A scrambled siRNA was used as control. 24 hr after seeding, 
HUVECs were transfected using Lipofectamine® RNAiMax according to manufacturer’s 
instructions (Life Technologies, Invitrogen, Ghent, Belgium), the next day, cells were reseeded 
and treated as indicated. LENTIVIRAL TRANSDUCTIONS: to generate stable cell lines, lentiviral 
shRNA vectors against human or murine ATG5 were purchased from Sigma-Aldrich 
(MISSION® shRNA library Sigma-Aldrich, Bornem, Belgium). Oligonucleotide sequences are 
 available upon request. An empty vector (for B16-F10 experiments) or nonsense scramble 
shRNA (for HUVEC experiments) was used as a negative control. Production of lentiviruses 
by transfection into 293T cells was as described (Carlotti et al., 2004). For transductions, a 
multiplicity of infection (MOI) of 10 for ATG5 silencing was used. Cells were transduced 
overnight in the presence of 0.5 μg/mL polybrene (Sigma-Aldrich, Bornem, Belgium), and re-
fed with fresh medium the next day. Selection was performed with 4 μg/mL puromycin.  
IN VITRO FUNCTIONAL ASSAYS: AUTOPHAGY: Autophagy was analysed via Western blot 
determination of LC3 II and p62 protein levels relative to actin according to published 
guidelines (Klionsky et al., 2012), in the absence or presence of the indicated concentrations 
of chloroquine to reveal the ON-state of autophagy (autophagic flux). The number of 
autophagosomes was analyzed by fluorescent confocal microscopic analysis after 
immunostaining for the autophagy marker LC3 of the paraformaldehyde fixed cells. CELL 
DEATH: Cells were trypsinised at the indicated time points and incubated with the vital dye 
propidium iodide (PI) at 2 µg/mL. PI-positive (dead) cells were quantified via flow cytometry 
(AttuneTM Cytometer, Invitrogen, Life Technologies, Paris, France). PROLIFERATION: was 
quantified by incubating cells for 2 hr with 1 μCi/mL [3H]-thymidine. Thereafter, cells were fixed 
with 100% ethanol for 15 min at 4 °C, precipitated with 10% trichloric acid and lysed with 0.1 N 
NaOH. The amount of [3H]-thymidine incorporated into DNA was measured by scintillation 
counting (Scintillation counter Perkin Elmer, Zaventem, Belgium). CLONOGENIC GROWTH: Cells 
were plated as single cell suspension at very low density (500 cells per 10 cm dish). After 
growth for 7 days, cells were fixed in methanol containing 1% methylene blue. SPHEROID 
CAPILLARY SPROUTING ASSAY: HUVECs (1,000 cells with or without transduction with lentiviral 
shATG5 or transfection with siNotch1, siNotch2, siNotch3 or siNotch4) were incubated 
overnight in hanging drops in EGM2 medium (Clonetics) containing 20% methylcellulose to 
form spheroids. Spheroids were then embedded in collagen gel as described (Korff et al., 
2004) and cultured for 24 hr to induce sprouting. CQ and/or DAPT were added at the indicated 
concentrations during the collagen gel culture step, using corresponding vehicle 
concentrations as control. Cultures were fixed and images were captured with a Zeiss laser 
scanning Meta NLO microscope (Carl Zeiss, Munich, Germany). Analysis of the number of 
primary sprouts, branches and the total sprout length (cumulative length of primary sprouts 
and branches per spheroid) was performed using NIH ImageJ. SCRATCH WOUND MIGRATION 
 ASSAY: was performed with HUVECs on gelatin/BSA coated 24-wells after overnight 
pretreatment with CQ. A scratch wound was applied on the confluent HUVEC monolayer 
using a 200 µL tip. After scratch wounding and photography (T0), the cultures were further 
incubated for the indicated time periods, and photographed again (Tx). Migration 
distance (gap area at T0 minus gap area at Tx) was measured with NIH ImageJ software and 
is expressed in arbitrary units. COLLAGEN INVASION ASSAY: Cancer cells were seeded on 
Matrigel gels and invasion into the gel was quantified after 48 hr by scoring the area of cancer 
cells invading into the Matrigel (Gaggioli et al., 2007). γ-SECRETASE CATALYTIC ACTIVITY ASSAY: 
was performed using an adapted version of the γ-secretase in vitro activity assay, originally 
developed by Kakuda et al. and modified by Chavez-Gutierrez et al. (Chavez-Gutierrez et al., 
2012; Kakuda et al., 2006). Enzyme preparation: γ-secretase containing microsomes were 
obtained from HEK cells via cell-cracking based homogenization in 20 mM PIPES (pH 7.0), 
140 mM KCl, 0.25 M sucrose, 5 mM EGTA with Complete Protease Inhibitor (PI) cocktail 
(Roche), and subsequent 10 min centrifugation of the homogenate at 800 g followed by ultra-
centrifugation of the supernatant for 1 hr at 100,000 g. The microsomal pellet thus obtained 
was dissolved to a final concentration of 5 mg/mL in 50 mM citric acid (pH 6.7), 0.25 M 
sucrose, 1 mM EGTA solution containing 1% CHAPSO and Complete EDTA-free PI cocktail 
(Roche), and incubated on ice for 1 hr. The solubilized microsomes were finally recovered in 
the supernatant after an additional 1 hr centrifugation at 100,000 g. Substrate preparation: 
Substrate for the reaction (Notch1 transmembrane domain) was produced by transfecting 
COS cells (TransIT – transfection reagent (Mirus)) with a construct expressing the 14 kDa 
Notch1 transmembrane domain tagged with 3 Flag tags at its C-terminus (Chavez-Gutierrez et 
al., 2012). Substrate expressing cells were lysed in 1% NP40 (IgepalCA-630 (Sigma)) Tris-
buffered saline (TBS – 50 mM Tris-HCl, pH 7.6 150 mM NaCl) with Complete Protease 
Inhibitor (Roche) and the substrate was purified from the lysate using anti-Flag affinity M2-
agarose beads (Sigma). 100 mM glycine (pH 2.7) solution containing 0.0625% n-dodecyl 
beta-D-maltoside (DDM) detergent (Sigma) was used for substrate elution, which was 
immediately brought to physiological pH 7 using 1 M Tris-HCl (pH 8) buffer and concentrated 
4X by spinning the eluate through a porous, 3 KDa cut off membrane (Amicon Ultra, Ultracel 
3K MWCO (Milipore)). Quality controls, including Coomassie staining and Western blot 
analysis (using anti-Flag M2 antibody for detection) confirmed successful production of the 
 substrate. In vitro γ-secretase reaction: The reaction mixture consisted of 50 mM citric acid 
(pH 6.7), 0.25 M sucrose, 1 mM EGTA solution with the Complete EDTA-free Protease 
Inhibitor cocktail (Roche), to which substrate and the γ-secretase containing solubilized 
microsomes were added along with phosphatidylcholine (PC) (Sigma) (0.1% final 
concentration). The reaction mixture was incubated at 37°C for 4 hr without or with CQ (25 
μM), and using 10 μM DAPT/Inhibitor X as a positive control for γ-secretase inhibition. Prior to 
Western blot analysis of the reaction product, substrate-containing lipids were removed using 
methanol : chloroform (1:2) extraction. The water phase containing soluble product was then 
mixed with sample buffer, denaturated, and subjected to Western blotting using anti-Flag M2 
antibody and goat-anti-mouse IR800 antibodies for visualization of the NICD reaction product. 
Infrared signal was detected using the Odyssey Infrared Imaging System. CYCLOHEXIMIDE 
BASED CHASE ASSAY: HUVEC cells treated or not for 24 hr with CQ were incubated in the 
presence of the translation blocker cycloheximide (100 µg/mL final concentration) for 0 (cells 
before cycloheximide addition), 2, 4, 6, 8 and 10 hr. The cells were then lysed in Laemmli 
buffer (62.5 mM Tris-HCl pH 6.8; 10% glycerol; 2% SDS, containing protease and 
phosphatase inhibitor cocktail). Protein concentration was measured and equal amounts of 
protein were size-separated by electrophoresis on precast NuPAGE 3-8% polyacrylamide TA 
gels. The gels were then used for Western blot detection of the Notch1 cleavage bands and 
were processed, imaged using the Odyssey Infrared Imaging System and quantified as 
described above. CELL SURFACE BIOTINYLATION: Prior to the biotinylation reaction HUVEC were 
cultured for 24 hr in the EGM2 medium with or without CQ (25 μM). The entire cell surface 
biotinylation reaction was then performed on ice using 0.5 mg/mL EZ-LinkTMsulfo-NHS S-S 
Biotine (Pierce, Thermo Scientific) dissolved in PBS+/+ (pH 8) to label the free primary amine 
groups (e.g. lysine residues and/or protein amino termini) of surface localized proteins. 
Excessive biotin was removed by several subsequent washes (including a quenching step 
with 1% BSA) as previously described (Sannerud et al., 2011). The cells were lysed in 50 mM 
Hepes pH 7,2 buffer containing 100 mM NaCl, 1% TX-100, and protease inhibitor cocktail 
Complete (Roche). The mixture was then centrifuged for 10 min at 20,000 g, protein 
concentration in the post nuclear supernatants was determined, and equal amounts of 
proteins were subjected to an overnight pull-down reaction with streptavidin agarose beads 
(Pierce, Thermo Scientific) to recover biotinylated surface proteins. The beads were washed 
 several times, and bound protein was eluted in 2X loading buffer (Invitrogen) supplemented 
with 2% β-mercaptoethanol, at 70 °C for 10 min. The eluted proteins were then size-separated 
by electrophoresis on precast 3-8% NuPAGE polyacrylamide Tris Acetate gels (TA) (Novex, 
Life Technologies) and analyzed using standard Western blotting protocol. LUCIFERASE 
ACTIVITY ASSAY: Notch signaling in HUVECs was evaluated in cells transfected with a total of 1 
µg of appropriate plasmid DNA combination, using Fugene HD (Promega) transfection 
reagent. The pHES-1-Luc reporter plasmid, originating from the lab of A. Israel (Jarriault et al., 
1995), expressing firefly luciferase under the control of the HES1 promoter (containing 
CBF1/Su(H)/Lag1 (CSL) binding sites) was used. CQ treatment for 24, 48 or 72 hr was 
initiated 24 hr after transfection with this plasmid (kindly provided by Lutgarde Serneels, VIB - 
KU Leuven, Leuven, Belgium). To correct cell count and transfection efficacy, the pRL-TK 
plasmid (Promega), expressing Renilla luciferase under the control of the thymidine kinase 
promoter, was co-transfected as a normalization control. Activity of endogenous Notch1 was 
measured in pHES-1-Luc and pRL-TK (1:1) double transfected cells. Additionally, the 
alternative Cignal RBP-Jk reporter assay (Qiagen) was used to monitor the level of Notch 
signaling activity in HUVECs cultured with or without CQ for 12, 24, 48 or 72 hr. Therefore, a 
RBP-Jk responsive luciferase construct expressing firefly luciferase under the control of a 
minimal (m)CMV promoter and tandem repeats of the RBP-Jk (CBF1) transcriptional response 
element (TRE) was used, co-transfected with the constitutively expressing Renilla luciferase 
construct (Qiagen) as normalization control (in 40:1 ratio), and the cells were subjected to 
experimental conditions 24 hr after transduction. Luciferase activity was determined using the 
Dual luciferase reporter assay system (Promega), at 24, 48 or 72 hr (for HES1-luc assay) and 
12, 24, 48 or 72 hr (for RBP-Jk reporter assay) after the CQ stimulation. Luminescence was 
measured on a plate reader (Victor, Perkin Elmer) set to acquire 10 consecutive 1 s long 
measurements per sample. The averaged firefly luciferase signal was then normalized using 
the corresponding Renilla luciferase signal, and results were expressed as fold change versus 
the control condition. Experiments were performed using 3-6 replicates and were repeated at 
least 4 times. PROTEIN CONCENTRATION in lysates and purified cell fractions was determined 
using the BCA protein assay reagent (Pierce).   
 RNA & DNA ANALYSIS: RNA expression analysis was performed by Taqman quantitative 
RT-PCR as described (Geudens et al., 2010), using home-designed primers and probes or 
premade primer sets (Applied Biosystems, Carlsbad, CA). Primer and probes sequences or 
premade primer set ID numbers are available upon request.  
IMMUNOBLOT ANALYSIS: Protein extraction and immunoblot analysis were performed using a 
modified Laemmli sample buffer (125 mM Tris-HCl, pH 6.8 buffer containing 2% SDS and 
20% glycerol) in the presence of protease and phosphatase inhibitors (Roche, Vilvoorde, 
Belgium). Lysates were separated by SDS-PAGE under reducing conditions, transferred to a 
nitrocellulose or PVDF membrane, and analyzed by immunoblotting. Primary antibodies used 
were anti-p62 (Abcam, Cambridge, United Kingdom), anti LC3, anti-cleaved Notch1 
intracellular domain (NICD)(Val 1744), anti-C-terminal Notch1 (D1E11), and anti-lamin A/C (all 
from Cell Signaling Technology, Bioké, Leiden, the Netherlands), anti-β-actin (Sigma-Aldrich 
Bornem, Belgium). Appropriate secondary antibodies were from Dako (Enschede, the 
Netherlands), Molecular Probes® Invitrogen (Life Technologies, Ghent, Belgium) and Thermo 
Scientific (Erembodegem, Belgium). Signal was detected using the ECL system (Amersham 
Biosciences, GE Healthcare, Diegem, Belgium) and LICOR Odyssey CLx Western Blot 
Detection System (Westburg, Leusden, the Netherlands) according to the manufacturer’s 
instructions. Quantifications were done by densitometry of the bands using the NIH Image J 
software or Odyssey system software. 
HISTOLOGY, IMMUNOSTAININGS AND MORPHOMETRIC ANALYSES: All methods for histology 
and immunostaining have been described (Fischer et al., 2007). Cell cultures were fixed in 4% 
paraformaldehyde (PFA) for 10 min at 37 °C. Patient and mouse tissue samples were 
immediately frozen in OCT compound (for 7 µM and 40 µM serial sections) or fixed in 4% PFA 
overnight at 4 °C, dehydrated and embedded in paraffin (for 7 µM serial sections). 
Immunostainings were performed using the following primary antibodies: anti-CD63 and anti-
LC3 (Abcam, Cambridge, United Kingdom), anti-CD31 (BD Pharmingen, Erembodegem, 
Belgium), anti-α-smooth muscle actin-Cy3 (Sigma-Aldrich Bornem, Belgium), anti-FITC 
(Chemicon-Millipore, Billerica, MA, USA), anti-EEA1 and anti-LAMP-1 (both from BD 
Biosciences, Ermebodegem, Belgium), anti-NICD, anti-C-terminal Notch1, anti-VEGFR2, anti-
 PHH3 (all from Cell Signaling Technology, Bioké, Leiden, the Netherlands), anti-VEGFR1, 
anti-FGFR1, anti-PDGFRα, anti-Tie-2 (all from Santa Cruz Biotechnology, Heidelberg, 
Germany), anti-VE-cadherin (R&D systems, Minneapolis, MN, USA), anti-chloroquine (Novus 
Biologicals), anti-CD45 (Becton Dickinson, Erembodegem, Belgium). Sections were then 
incubated with the appropriate fluorescently conjugated secondary antibodies (Alexa 488 or 
546, Molecular Probes®, Invitrogen, Life Technologies, Ghent, Belgium) or with peroxidase-
labeled IgGs (Dako, Heverlee, Belgium), followed by amplification with the proper tyramide 
signal amplification systems when needed (Perkin Elmer, Life Sciences, Zaventem, Belgium). 
Nuclei were counterstained with DAPI. For morphometric analyses, 15-20 random optical 
fields (20x or 40x magnification) per tumor section or mosaic picture were taken by a Zeiss 
Axioplan upright microscope or Leica DMI 6000 B inverted microscope (Leica Microsystems, 
Mannheim, Germany) and analyzed using the NIH Image J or Leica MM AF powered by 
MetaMorph ® analysis software. Confocal imaging was performed using a Zeiss LSM 510 
Meta NLO or Zeiss LSM 780 confocal microscope (Carl Zeiss, Munich, Germany). TUMOR 
NECROSIS was assessed on H&E or Harris Haematoxylin (HH) stained paraffin sections. 
TUMOR HYPOXIA was detected after injection of 60 mg/kg pimonidazole hydrochloride 
(Hypoxyprobe kit, Chemicon-Millipore, Billerica, MA, USA) into tumor-bearing mice (tumors 
were harvested 1 hr after injection). To detect the formation of pimonidazole adducts, tumor 
paraffin sections were immunostained with Hypoxyprobe-1-Mab1 (Hypoxyprobe kit, 
Chemicon-Millipore, Billerica, MA, USA) following the manufacturer’s instructions. TUMOR 
VESSEL PERFUSION was quantified on tumor cryosections following intravenous injection of 0.05 
mg fluorescein-labeled Lycopersicon esculentum (Tomato) lectin (FL-1171, Vector 
laboratories) in tumor-bearing mice (tumors were harvested 10 min after injection). 
Percentage of perfused vessels was analyzed as the % of CD31-positive vessels colocalizing 
with lectin (NIH Image J software). VESSEL LEAKAGE was analyzed on tumor cryosections after 
intravenous injection of 0.25 mg FITC-conjugated dextran 40 kDa (Sigma-Aldrich, Bornem, 
Belgium) in tumor-bearing mice (tumors were harvested 10 min after injection).  Percentage of 
leaky vessels was measured as the % of dextran that was not colocalizing with CD31-positive 
vessels (NIH Image J software). TUMOR CELL PROLIFERATION was detected by immunostaining 
of B16-F10 and A375m tumor sections for Phospho-Histone 3 (PHH3). PHH3+ nuclei of tumor 
cells were considered as positive when they were exhibiting condensed chromosomes and a 
 mitotic spindle. Because histone H3 phosphorylation commences just before prophase, 
prophase nuclei are also PHH3-labeled. These PHH3+ nuclei were not considered as mitotic 
figures, since they lacked a mitotic spindle. We excluded cells that displayed hyperchromatic 
nuclei and apoptotic nuclei. APOPTOTIC CELL DEATH: was detected and quantitated via the 
transferase-mediated dUTP nick end-labeling (TUNEL) technique using the In situ Cell Death 
Detection Kit (Roche, United States) according to the manufacturer’s instructions. In brief, 
chamber paraffin slides were deparaffinized and permeabilized in 0.1% Triton X-100. The 
slides were then incubated with the TUNEL reaction mixture for 1 hr at 37 °C. The slides were 
washed with PBS, incubated with peroxidase-conjugated antibody for 30 min at 37 °C and 
developed with the Fluorescein system (Perkin Elmer). Mosaic pictures were taken, and 
TUNEL+ area was quantified and expressed as a % of total area of analyzed tumor.  
SCANNING ELECTRON MICROSCOPY: Small tumor pieces were fixed overnight in 2.5% 
glutaraldehyde in 0.1 M Na-cacodylate buffer, pH 7.2-7.4 at 4 °C. Three rinses of 30 min with 
0.1 M Na-cacodylate buffer were followed by vibratome sectioning (HM 650V, Thermo 
Scientific Microm, Loughborough, UK) of the tissues (400 μm) embedded in 5% low melting 
temperature SeaPlaque ® agarose (Lonza, Rockland, ME, USA). Sections were postfixed with 
2% osmiumtetroxide in 0.1 M Na-cacodylate buffer for 2 hr at room temperature. Following 
dehydration in a graded ethanol series (30-50-70-100%) the organs were critical-point dried 
(BAL-TEC CPD 030, Balzers, Germany). Critical-point dried tissues were mounted on stubs 
with double-sided adhesive carbon tape. The stubs were coated with gold (SPI-MODULETM 
Sputter Coater, SPI Supplies, West Chester, PA, USA). Images were obtained with a 
scanning electron microscope (JEOL JSM-6360, Tokyo, Japan) at 10 kV (KU Leuven, 
Molecular Physiology of Plants and Micro-organisms Section). 
TUMOR MODELS: SUBCUTANEOUS TUMOR GROWTH: Two subcutaneous melanoma tumor 
models were used: B16-F10 (murine) and A375m (human). Adherent growing cells were 
harvested and single-cell suspensions of 150,000 cells in 100 μL (B16-F10) or 300,000 cells in 
100 μL (A375m) of PBS were injected subcutaneously into the right flank of immunocompetent 
syngeneic (C57/Bl6) or immunodeficient mice (nu/nu), respectively. Tumor volumes were 
measured three times a week with a caliper using the formula: V = π x [d2 x D] / 6, where d is 
 the minor tumor axis and D is the major tumor axis. The mice were sacrificed at defined time 
intervals after cell inoculation or when tumors reached a maximum size of 2,000 mm3 (B16-
F10) or 1,000 mm3 (A375m). Tumors and lungs were collected for histological analysis, gene 
expression or protein analysis. For the B16-F10 model, lung nodules were counted under a 
stereoscopic microscope and metastatic index was determined by normalizing the number of 
metastases for the tumor weight. Percentage of pulmonary metastasis area was measured on 
H&E stained sections as the % of total lung area. All tumor growth experiments were repeated 
at least 2 times, each experiment comprising 7 to 11 mice per group (unless otherwise 
indicated). Treatment with CQ was started when tumors reached an average size of 100 mm3. 
Mice received daily intraperitoneal injections of CQ (50 mg/kg or 100 mg/kg) or saline 
solutions as control. Treatment with suboptimal doses of dacarbazine (5-(3,3-Dimethyl-1-
triazenyl) imidazole-4-carboxamide; DTIC) 40 mg/kg by intraperitoneal injections for 4 days 
was started 7 days after the initiation of the CQ-treatment. Treatment with suboptimal doses of 
cisplatin 2.5 mg/kg every other day by intraperitoneal injections for 7 days was started at 7 
days after the initiation of CQ-treatment. To assess tumor drug delivery, a single high dose (10 
mg/kg) cisplatin was injected intraperitoneally 8 hr before euthanization of the mice. 
DETECTION OF CIRCULATING TUMOR CELLS (CTCS): 100 μL blood samples were collected from 
B16-F10 tumor bearing mice at the end stage of the experiment.  Blood samples were 
collected in RNAprotect Animal Blood Tubes (Qiagen) and RNA was extracted with RNeasy 
Protect Animal Blood Kit (Qiagen), according to the manufacturer’s instructions. The level of 
CTCs was analyzed by assessing MelanA transcript levels normalized to Hprt transcript 
levels.  
GC-MS ANALYSIS OF CQ: PREPARATION OF STANDARD CURVE FOR QUANTIFICATION OF 
CHLOROQUINE AND CQ EXTRACTION FROM TUMOR: Different amounts of chloroquine (blank, 100 
µg, 50 µg, 25 µg, 10 µg, 5 µg, 1 µg, 500 ng, 100 ng) were dissolved in 300 µL of PBS. 
Extraction of chloroquine from the tumor samples was performed as previously described 
(Keller et al., 1998) with some adaptations. Mice that were injected with chloroquine or PBS 
were euthanized 1 hr following treatment and tumors were snap-frozen immediately after 
dissection. Briefly, 400 µL of a 5% NH4OH solution was added to tumor and homogenized. 
Next, 500 µL of ethylacetate was added and the solution was vortexed thoroughly and 
 centrifuged at 20,000 g for 15 min at 25 °C. The clear supernatant was then transferred to a 
new eppendorf tube and dried using a vacuum centrifugator. The dried pellets were stored at -
80 °C until further usage. Protein content in analyzed tumor was analyzed by BCA. MASS 
SPECTROMETRIC ANALYSIS OF CHLOROQUINE: To the dried fractions 80 µL of N,O-
Bis(trimethylsilyl)-trifluoroacetamide (Sigma-Aldrich, Steinheim, Germany) was added, the 
reaction was carried out for 2.5 hr at 37 °C. Reaction mixtures were centrifuged for 15 min at 
20,000 g at 25 °C in order to remove insolubilities and the supernatant was transferred to a 
glass vial with conical insert (Agilent). GC/MS/MS analyses were performed using an Agilent 
7890A GC equipped with a HP-5 MS 5% Phenyl Methyl Silox (30 m - 0.25 mm i.d. - 0.25 μm; 
Agilent Technologies, Santa Clara, California, USA) capillary column, interfaced with a triple 
quadruple tandem mass spectrometer (Agilent 7000B, Agilent Technologies) operating under 
ionization by electron impact at 70 eV. The injection port, interface, and ion source 
temperatures were kept at 250 °C. Temperature of the quadrupoles was maintained at 150 °C. 
The injection volume was 1 μL, and samples were injected in splitless mode. Helium flow was 
kept at 1 mL/min. The temperature of the column started at 100 °C for 2 min and increased to 
300 °C at 50 °C/min, and held for 3 min (total run time 9 min). After the gradient, the column 
was heated for another 3 min at 325 °C. The GC/MS/MS analyses were performed in Multiple 
Reaction Monitoring mode (MRM) scanning for a parent mass (Q1) with m/z 319.6. Nitrogen 
was used as the collision gas to achieve collision induced dissociation (CID) in Q2. The 
collision gas flow was kept at 1.5 mL/min and a He quench flow of 2.25 mL/min was applied, 
the collision energy was set at 5 eV resulting in a daughter ion of 290.2 (Q3). For the 
quantification of chloroquine we integrated the ion current of the parent mass using 
MassHunter GC/MS acquisition software. Each sample was run in triplicate. 
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